| Nov 17 |
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop
|
| Nov 14 |
Kyverna Therapeutics GAAP EPS of -$0.80
|
| Nov 14 |
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
|
| Nov 13 |
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
|
| Oct 21 |
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
|
| Oct 19 |
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy
|
| Oct 10 |
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc
|
| Oct 10 |
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential
|
| Sep 18 |
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
|
| Sep 16 |
Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
|
